Nuvation Bio (NUVB) Non-Current Assets (2020 - 2026)
Nuvation Bio (NUVB) posted quarterly Non-Current Assets of $18.7 million for Q1 2026, up 10.58% year-over-year from $16.9 million in Q1 2025, and down 19.7% quarter-over-quarter from $23.3 million in Q4 2025.
Nuvation Bio (NUVB) Non-Current Assets (2020 - 2026) Analysis & Trends
Nuvation Bio (NUVB) has reported Non-Current Assets for 7 consecutive years, with $18.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets rose 10.58% year-over-year to $18.7 million; the TTM figure through Mar 2026 stood at $90.1 million (up 97.89% YoY), while the FY2025 annual figure was $23.3 million, up 62.15% from the prior year.
- Non-Current Assets retreated to $18.7 million in Q1 2026 per NUVB's latest filing, from $23.3 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $24.0 million in Q3 2025 and bottomed at $3.8 million in Q1 2022.
- Historically, Non-Current Assets has averaged $10.5 million across 5 years, with a median of $5.5 million in 2023.
- Annual changes were most pronounced in 2022 — Non-Current Assets jumped 361.16% — and 2023, when it declined 23.57%.
- Nuvation Bio's Non-Current Assets stood at $4.8 million in 2022, then gained by 4.71% to $5.0 million in 2023, then jumped by 184.57% to $14.4 million in 2024, then surged by 62.15% to $23.3 million in 2025, then fell by 19.7% to $18.7 million in 2026.
- Business Quant data shows NUVB's Non-Current Assets at $18.7 million in Q1 2026, $23.3 million in Q4 2025, and $24.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Nuvation Bio | 2.16 Bn | 2.16 Bn | 30.78 Mn | 18.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.07 Mn |
| Mar 31, 2026 | 18.71 Mn |
| Dec 31, 2025 | 23.30 Mn |
| Sep 30, 2025 | 24.03 Mn |
| Jun 30, 2025 | 24.02 Mn |
| Mar 31, 2025 | 16.92 Mn |
| Dec 31, 2024 | 14.37 Mn |
| Sep 30, 2024 | 6.59 Mn |
| Jun 30, 2024 | 7.62 Mn |
| Mar 31, 2024 | 5.07 Mn |
| Dec 31, 2023 | 5.05 Mn |
| Sep 30, 2023 | 5.52 Mn |
| Jun 30, 2023 | 4.18 Mn |
| Mar 31, 2023 | 4.50 Mn |
| Dec 31, 2022 | 4.82 Mn |
| Sep 30, 2022 | 5.10 Mn |
| Jun 30, 2022 | 5.47 Mn |
| Mar 31, 2022 | 3.77 Mn |
| Dec 31, 2021 | 4.08 Mn |
| Sep 30, 2021 | 1.18 Mn |